RESEARCH ARTICLE

Bacteremia in Children Hospitalized with Respiratory Syncytial Virus Infection

Miriam Cebey-López1,2*, Jacobo Pardo-Seco1,2,3, Alberto Gómez-Carballa1,2,3, Nazareth Martínón-Torres1,2, José María Martínón-Sánchez1,2, Antonio Justicia-Grande1,2, Irene Rivero-Calle1,2, Elli Pinnock4, Antonio Salas1,3, Colin Fink4, Federico Martínón-Torres1,2*, GENDRES network¶

1 Grupo de Investigación en Genética, Vacunas, Infecciones y Pediatría (GENVIP - www.genvip.org), Hospital Clínico Universitario and Universidade de Santiago de Compostela (USC), Galicia, Spain, 2 Translational Pediatrics and Infectious Diseases Section, Department of Pediatrics, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Galicia, Spain, 3 Unidade de Xenética, Departamento de Anatomía Patológica e Ciencias Forenses, and Instituto de Ciencias Forenses, Grupo de Medicina Xenómica (GMX), Facultade de Medicina, Universidade de Santiago de Compostela, Galicia, Spain, 4 Micropathology Ltd., University of Warwick Science Park, Coventry, United Kingdom

☯ These authors contributed equally to this work.
¶ The complete membership of the author group can be found in the Acknowledgments.
* federico.martinon.torres@sergas.es

Abstract

Background

The risk of bacteremia is considered low in children with acute bronchiolitis. However the rate of occult bacteremia in infants with RSV infection is not well established. The aim was to determine the actual rate and predictive factors of bacteremia in children admitted to hospital due to confirmed RSV acute respiratory illness (ARI), using both conventional culture and molecular techniques.

Methods

A prospective multicenter study (GENDRES-network) was conducted between 2011–2013 in children under the age of two admitted to hospital because of an ARI. Among those RSV-positive, bacterial presence in blood was assessed using PCR for Meningococcus, Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus, in addition to conventional culture and molecular techniques.

Results

66 children with positive RSV respiratory illness were included. In 10.6% patients, bacterial presence was detected: H. influenzae (n = 4) and S. pneumoniae (n = 2). In those patients with bacteremia, there was a previous suspicion of bacterial superinfection and had received empirical antibiotic treatment 6 out of 7 (85.7%) patients. There were significant differences in terms of severity between children with positive bacterial PCR and those with negative results: PICU admission (100% vs. 50%, P-value = 0.015); respiratory support
necessity (100% vs. 18.6%, \(P\)-value < 0.001); Wood-Downes score (mean = 8.7 vs. 4.8 points, \(P\)-value < 0.001); GENVIP scale (mean = 17 vs. 10.1, \(P\)-value < 0.001); and length of hospitalization (mean = 12.1 vs. 7.5 days, \(P\)-value = 0.007).

**Conclusion**

Bacteremia is not frequent in infants hospitalized with RSV respiratory infection, however, it should be considered in the most severe cases.

**Introduction**

Respiratory syncytial virus (RSV) is the main cause of viral acute respiratory infection and leads to hospitalization in infants and young children worldwide, being responsible for 60% to 80% of hospitalizations for bronchiolitis [1]. The main complication of viral respiratory infections is bacterial co-infection and respiratory failure. The synergism between virus and bacteria has been widely discussed in the literature, particularly for respiratory viruses and secondary bacterial pneumonia [2]. Bacteremia rates reported in children with respiratory illness are low, with rates <1.2% in RSV—confirmed cases [3–7]. In those requiring mechanical ventilation, bacterial co-infection rates in respiratory samples are consistently higher but may vary, ranging from 21.0% to 43.9% [8,9]. However, the prevalence, clinical phenotype and course of bacteremia with pathogenic bacteria in the setting of acute RSV infection in infants with no other risk factors, are questions that have not been investigated in sufficient detail, even less with the use of molecular diagnostics.

The aim of this study was to determine the actual rate and predictive factors of bacteremia in children admitted to hospital due to confirmed RSV acute respiratory illness using both conventional culture and molecular techniques.

**Materials and Methods**

**Study design and recruitment criteria**

This is an observational prospective sub-study performed from January 2011 to January 2013, in the framework of GENDRES (Genetic, Vitamin D and Respiratory Infections Research Network – www.gendres.org), a research network on pediatric acute respiratory infections that includes 13 Spanish tertiary hospitals. For this study, previously healthy infants under the age of two admitted to any of the participant hospitals in the GENDRES network with confirmed RSV infection were included. Patients with a history of known immunodeficiency, severe cardiac anomaly, severe chronic lung disease, neuromuscular disease, chromosomal abnormalities or any ongoing chronic disease were excluded from the study. A complete clinical record, a blood sample and a nasopharyngeal sample were collected in all included participants.

The severity of each respiratory episode was ranked as follows: 1) physician criteria (mild, moderate or severe); 2) Wood-Downes scale (0 to 10 points; mild < 3, moderate 4–7, severe > 8); and 3) a newly developed scale -named GENVIP score- (0 to 20 points) that assesses food tolerance, degree of medical intervention needed, respiratory distress, respiratory frequency, apnea, malaise and fever (article in preparation; data in S1 Table [10]).

The study was performed according to Good Epidemiological Practice and written informed consent was obtained from a parent or legal guardian for each subject before study inclusion. The study was approved by the Ethics Committee of Clinical Investigation of Galicia (CEIC ref 2010/015).

---

**Competing Interests:** The authors have declared that no competing interests exist.
Clinical data collection and laboratory methods

The patients’ clinical and demographic data were collected using a secure web-based platform. RSV status was determined both by conventional methods/rapid test in the referring hospital, and by molecular techniques in nasopharyngeal secretions. For RSV assessment by molecular techniques, a nasopharyngeal sample was obtained for the study during hospitalization, using either a sterile feeding tube and injector for nasopharyngeal aspirate/wash, or a sterile nylon swab (FLOQSwabsTM by Copan Diagnostics, Brescia, Italy), without culture medium. A panel of 19 viruses including RSV was sought by nested polymerase chain reaction (PCR). Methods were previously described in Cebey-López et al. [11].

A peripheral blood sample for analysis was also collected from each patient at the same time as the swab, in an EDTA BD Vacutainer® K3E 3.4 mg tube (Becton Dickinson, Franklin Lakes, Plymouth, UK). In some patients, the initial conventional bacterial test was performed on hospital admission samples, whilst PCR was performed using samples obtained after the patients were transferred to PICU and recruited into the study. PCR results were not shared with clinicians due to all PCR were performed simultaneously off-patient. Blood samples were pretreated as follows: 250ul of blood was mixed with 25ul lysozyme (100 mg/ml, Sigma-Aldrich, St Louis, Missouri, USA) and 10ul lysostaphin (1mg/ml, Sigma-Aldrich, St Louis, Missouri, USA), vortexed briefly and incubated at 37°C for 30 minutes. 0.1g lysing matrix B beads (MP Biomedicals, Santa Ana, California, USA) were added and the mixture was agitated at 30Hz for 2x30s using a TissueLyser II (Qiagen, Hilden, Germany). 200ul lysis buffer AL (Qiagen, Hilden, Germany) was added and the samples were centrifuged at 5,500 rpm for 2 minutes to pellet the lysis beads. 200ul of the lysed blood sample was then transferred onto a Biorobot MDx (Qiagen, Hilden, Germany) and total nucleic acid extracted using silica membrane chemistry and eluted in 200ul of elution buffer AE (QIAamp DNA Blood Biorobot MDx extraction kit, Qiagen, Hilden, Germany).

Nested PCR was then performed to detect the presence of ten different organisms, as below (Table 1).

The PCRs were performed as two screens, with the first round reactions multiplexed for targets 1–5 and 6–10 respectively. All first round reactions were performed in 50ul reaction volumes consisting of 20ul template (nucleic acid extracted from blood as described above) and 30ul mastermix (MyTaqHS, Bioline Reagents, London, UK) with each primer added to a final reaction concentration of 0.2uM. Thermal cycling conditions for the first round reactions were: 95°C for 2 minutes followed by 30 cycles of 95°C for 15s, 55°C for 15s, 72°C for 15s; this was performed using a TRIO block thermocycler (Biometra Gmbh, Göttingen, Germany).

**Table 1. Target genes and organisms detected by nested PCR.**

| Organism                        | Target gene | Amplicon size (bp) |
|---------------------------------|-------------|--------------------|
| Neisseria meningitides          | porA        | 947                |
| Streptococcus pneumoniae        | ply         | 209                |
| Haemophilus influenzae          | P6OMP       | 353                |
| Group A Streptococcus           | mf          | 419                |
| Group B Streptococcus           | cfb         | 154                |
| Acinobacter baumanii            | gltA        | 155                |
| Klebsiella pneumoniae           | mdh         | 193                |
| Pseudomonas aeruginosa          | oprL        | 163                |
| Escherichia coli                | phoA        | 196                |
| Staphylococcus aureus           | femA        | 95                 |

doi:10.1371/journal.pone.0146599.t001
of first round template was transferred into 24ul of second round mastermix (MyTaqHS mastermix, Bioline Reagents, London, UK) containing second round primers at a final reaction concentration of 0.2uM for each primer and 1ul of Evagreen (Biotium, Hayward, California, USA) per reaction. Second round reactions were performed on a Lightcycler 480 (Hoffman-La Roche, Basel, Switzerland) using the following cycling conditions: 95°C for 2 minutes followed by 30 cycles of 95°C for 20s, 55°C for 20s, 76°C for 20s with fluorescence acquisition at 76°C. This was followed by a melt curve in which fluorescence was acquired from 75–95°C and melt curve analysis used to detect specific amplification.

DNA extraction and PCR amplification of bacterial targets was performed by a commercial referral laboratory, Micropathology Ltd (MCP). MCP is accredited by Clinical Pathology Accreditation (UK) Ltd (CPA, a subsidiary of UKAS) to provide diagnostic pathology services in the UK. All molecular PCR assays are validated to CPA standards. This process includes primer specificity checking by an in-house method based on analysis of publicly available sequence data to ensure that observed variation within each species is accounted for and that no cross-reactivity to other targets can be identified. The sensitivity of the PCRs for all ten targets is <5 gene copies/reaction. This was derived using a combination of quantitated PCR control material (AmpliRun, Vircell, Granada, Spain) and synthetic copies of the target amplicon, quantitated using an automated electrophoresis platform (MultiNA, Shimadzu, Kyoto, Japan).

Bacteremia was defined as the positivity of PCR and/or blood culture. Bacterial superinfection diagnosis relied on the discretion of the recruiting physician according to clinical data, inflammatory markers, radiological findings and/or appropriate cultures. PCR was done after children discharge so results were not shared with clinicians. All PCR were performed simultaneously off-patient. Respiratory support was considered as either invasive (mechanical ventilation) or non-invasive ventilation (CPAP, BiPAP). The severity of each respiratory episode was ranked by physician criteria (mild, moderate or severe). The respiratory distress was rated in the worst moment of the illness. Spanish national immunization program includes Hib vaccine but not pneumococcal conjugate vaccine. However average vaccination coverage with pneumococcal conjugate vaccine is estimated to be 60–65% through the private market.

Data analysis

We performed all the analyses using R Software, version 3.0.2 (http://www.r-project.org). General data are presented as percentages or means with 95% confidence intervals. Different statistical tests were used to assess the association between the variables: Fisher’s exact test for discrete variables and Wilcoxon test for continuous variables.

Results

Out of 130 eligible patients, 66 were RSV positive (data in S1 Fig). 92.4% of these (n = 61) were <12 months of age and the majority (66.7%) of the patients were boys. All children were correctly vaccinated according to the recommended national immunization schedule. Diagnosis at discharge was predominantly bronchiolitis 78.8% (n = 54) and pneumonia 6.1% (n = 4)

34.9% (n = 23) of the RSV positive patients had a suspected bacterial superinfection according to the referring physician. Molecular assessment revealed bacterial presence in the blood of seven (10.6%) patients (Table 2). No differences were found between those with negative or positive PCR in terms of sex distribution, age, family history, vaccination rate, diagnosis or suspicion of bacterial superinfection. There were significant differences in terms of illness severity between children with positive bacterial PCR and those with negative results: PICU admission (100% vs. 50%, P-value = 0.015) and respiratory support necessity (100% vs. 18.6%, P-value < 0.001). Patients with confirmed bacteremia had a more severe respiratory affection.
than those with no bacteria identified in blood (Table 2). Both the Wood-Downes score and the GENVIP scale indicated a worse value in the blood PCR positive patients (mean = 8.7 points and 17.0 points, respectively) than in the blood PCR negative patients (mean = 4.8 points and 10.1 points) (P-value < 0.001 for both). Hospitalization was longer for children with PCR-confirmed bacteremia (mean = 12.1 vs. 7.5 days, P-value = 0.007) (Fig 1).

The pathogen found were *H. influenzae* (n = 4), *S. pneumoniae* (n = 1) and both simultaneously (n = 2). The cycle thresholds were <20 except for S. pneumoniae in the co-infection
cases, in which the cycle threshold was >25. Only in one of these cases this bacteria had also been identified by conventional cultures.

In nasopharyngeal samples, more than one virus was detected in 35 out of 66 (53.0%) patients by molecular techniques. In bacterial PCR positive patients, viral co-infection was observed in 5 out of 7 (71.4%) subjects (Table 3). 30 patients with viral co-infection and negative PCR were identified (n = 24 patients with two virus and n = 6 with three virus). No statistical differences were observed in terms of viral co-infection between positive and negative bacterial PCR (P-value = 0.433)

Antibiotic administration in patients with suspected bacterial superinfection was recorded in 50.0% (n = 33) of the RSV-infected patients and in 3.3% (n = 1) of these patients a bacterial superinfection was confirmed by conventional blood cultures. In the patients with confirmed bacteremia by PCR, n = 6 patients were treated with antibiotics due to suspected bacterial superinfection. In these 6 patients, wide spectrum antibiotics were used.

There was no correlation between the patients suspected of superinfection and/or prescribed antibiotic by the referring physician, and those with positive blood PCR results (Cohen’s kappa coefficient bacterial superinfection-PCR = 0.15). A total of 87.5% of the patients presented fever; > 38°C in 50% of the included children (24 out of 48), and low-grade fever in 18 of them (37.5%). Fever frequency in children with bacteremia confirmed by PCR was similar to that in the rest of the cohort (P-value = 0.733).

### Discussion

One out of every ten previously healthy children hospitalized due to RSV had bacteremia, and these patients experienced a more severe disease. Conversely, half of the remaining RSV patients included, received empirical antibiotic therapy despite the bacteremia work-up result was negative.

The prevalence of bacteremia in children with RSV infection reported in the literature is low, ranging between 0.6 and 1.1% [3–5,12–14]. Our study found rates of concurrent bacteremia ten times higher (10.6%). In the studies cited, only conventional cultures were performed.
whereas molecular methods were applied in our series. RSV has been linked to seasonal increases in *S. pneumoniae* disease [15], as well as to other viruses such as influenza, but the underlying mechanisms between viral and bacterial synergism are complex and remain unclear. Immunization programs with conjugate vaccines against invasive *H. influenzae* serotype b and *Streptococcus pneumoniae* have changed the frequency of bacteremia in febrile infants (10,13). In our series, only 14.3% of the PCR positive patients had been vaccinated against pneumococcal disease, as compared to PCR negative ones, with 52.5% having received the vaccine. Animal studies found important mechanism of viral–bacterial synergy between bovine RSV and Histophilus somni and other bacterial pathogens [16]. This could indicate that RSV and *H.influenzae* have the same infection pattern in human patients.

The diagnosis of bacterial superinfection is most often made on clinical grounds, and not always confirmed microbiologically. Antibiotics should not be administered to RSV-infected children unless complications such as secondary bacterial illness occur [17,18]. In our series, blood cultures were not carried out systematically, but only when a bacterial superinfection was suspected by the referring physician. Blood culture is considered the gold standard for bacteria detection, but has a low sensitivity and some bacteria are difficult to culture. Blood PCR—much more sensitive—was performed in all the recruited patients but the clinical relevance of its positive result is not clear. Detecting circulating DNA in the blood by PCR has some limitations and it is essential to extrapolate always the results obtained to the clinical grounds to see if both PCR results and the clinical phenotype are consistent [19]. The quantitative PCR and the cycle threshold value are inversely correlated with the bacteria load and could be an indicator to avoid false positive results. In our cohort the cycle threshold was <20, but as we only have seven positive samples we could not establish maximum cutoff levels.

In our series, the physician suspected bacterial superinfection in half of the cases, a proportion similar to that in Thibeault et al.’s study [20]. Even though a blood culture was obtained for many of our patients (60.0%), only 3.8% (*n* = 1) yielded a positive result. Furthermore, we failed to find any correlation between PCR-confirmed bacteremia and clinical suspicion of bacterial superinfection (Cohen’s kappa coefficient = 0.15). Therefore, in agreement with other studies [14,21], we found that children with uncomplicated bacterial RSV infection are often overtreated with empirical antibiotics.

Empirical antibiotic treatment is often prescribed in practice to children hospitalized due to a confirmed viral ARI based on fever presence or persistence. Between 23 and 31% of cases of bronchiolitis are associated with fever [22], and in our series the fever rate (37 and 50%) was in the range previously described of 45 to 65% for children hospitalized with RSV [23]. However, the risk of bacteremia is low in febrile children with bronchiolitis [4,6,22], as corroborated in our series, where fever was not a predictor for bacteremia (*P*-value = 0.733).

Randolph et al. [9] studied the risk of bacterial infection in children infected with RSV admitted to PICU, and using blood culture they found a rate of bacteremia of only 0.6%. In our study, the rate of bacteremia found by PCR in children who required PICU admission is higher (25.0%), probably due to the higher sensitivity of molecular techniques. Bacteremic patients had a more severe course according to PICU admission rates, respiratory support necessity, clinical scales and length of hospitalization. Bloomfield et al. [14] suggest that empirical antibiotics should be considered for any child admitted to PICU with a RSV infection and requiring ventilator. In our series only half the patients who were admitted to PICU and required ventilatory support had a bacteremia revealed by PCR, meaning that antibiotic prescription might be superfluous in up to 50% of the cases. However, PCR was only performed in blood, meaning that we would be only excluding systemic bacterial infection, but not all forms of bacterial superinfection. On the other hand, due to the limited number of bacteremic subjects in our study, further studies are needed to make robust conclusions with regards to the overuse or underuse of antibiotic therapy.
In conclusion, our data show that concurrent bacteremia is not frequent in infants that are hospitalized with RSV respiratory infection, even in the presence of fever, and despite the use of molecular techniques for the diagnosis. However, bacteremia may actually occur and it should be suspected in the more severe cases, although our sample size did not allow us to find a reliable predictive clinical pattern. Antibiotics are frequently overused in the setting of RSV infection, and a more judicious approach to prescription should be warranted.

Supporting Information

S1 Fig. Flow chart of the study population.

(TIF)

S1 Table. GENVIP Score. Clinical severity score for healthy infants with respiratory infections.

(DOCX)

Acknowledgments

The authors thank the study investigators of the GENDRES network (www.gendres.org) for their effort recruiting children: Miriam Cehey López, Antonio Salas Ellacuriaga, Ana Vega Gliemmo, José Peña Guitián, Alex Regueiro, Antonio Justicia Grande, Leticia Pías Peleteiro, María López Sousa, María José de Castro, Carmen Curros Novo, Elena Rodrigo, Miriam Puente Puig, Rosaura Leis Trabazo, Nazareth Martínón-Torres, Alberto Gómez Carballa, Jacobo Pardo Seco, Antonio Justicia Grande, José María Martínón Sánchez, Belén Mosquera Pérez, Isabel Villanueva González, Lorenzo Redondo Coliázo, Carmen Rodríguez-Tenreiro and Federico Martínón Torres (Área Asistencial Integrada de Pediatría and GENVIP, Hospital Clínico Universitario, Santiago de Compostela); Máximo Francisco Fraga Rodríguez, Orlando Fernández Lago, José Ramón Antúnez (Biobank, Servicio Anatomía Patológica, Hospital Clínico Universitario, Santiago de Compostela); Enrique Bernaola Iturbe, Laura Moreno Galarraga, Jorge Álvarez (Hospital Materno Infantil Virgen del Camino, Pamplona); Teresa González López, Delfina Suarez Vázquez, Ángela Vázquez Vázquez, Susana Rey García (Complejo Hospitalario Universitario de Orense); Francisco Giménez Sánchez, Miguel Sánchez Forte (Hospital Universitario de Santiago de Compostela); Cristina Calvo Rey, María Luz García García (Hospital Severo Ochoa de Madrid); Ignacio Oulego Erroz, David Naranjo Vivas, Santiago Lapeña, Paula Alonso Quintela, Jorge Martínez Sáenz de Juderia, Estibaliz Garrido García (Hospital de León); Cristina CalvoHonge, Eider Oñate Vergara (Hospital de Donostia, San Sebastián); Jesús de la Cruz Moreno, Mª Carmen Martínez Padilla, Eugenia Villanueva Martínez, Ana González Espín (Complejo Hospitalario de Jaén); Manuel Baca Cots (Hospital Quirón, Málaga), David Moreno Pérez, Ana Cordón Martínez, Antonio Urda Cardona, José Miguel Ramos Fernández, Esmeralda Núñez Cuadros (Hospital Carlos Haya, Málaga); Susana Beatriz Reyes, María Cruz León León (Hospital Virgen de la Arrixaca, Murcia). Further details may be consulted at http://www.gendres.org or www.genvip.eu.

We also extend our gratitude to the children and parents/guardians who participated in this study and to the nursery and laboratory services from the Hospital Clínico Universitario de Santiago de Compostela for their effort.

Author Contributions

Conceived and designed the experiments: FMT MCL JPS NMT IR AJ JMS. Performed the experiments: EP CF. Analyzed the data: MCL JPS. Contributed reagents/materials/analysis tools: EP CF. Wrote the paper: MCL FMT AS AGC.
References

1. Jartti T, Soderlund-Venermo M, Hedman K, Ruuskanen O, Makela MJ (2013) New molecular virus detection methods and their clinical value in lower respiratory tract infections in children. Paediatr Respir Rev 14: 38–45. doi: 10.1016/j.prrv.2012.04.002 PMID: 23347659

2. McCullers JA (2006) Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 19: 571–582. PMID: 16947087

3. Levine DA, Platt SL, Dayan PS, Macias CG, Zorc JJ, et al. (2004) Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections. Pediatrics 113: 1728–1734. PMID: 15173498

4. Titus MO, Wright SW (2003) Prevalence of serious bacterial infections in febrile infants with respiratory syncytial virus infection. Pediatrics 112: 282–284. PMID: 12897274

5. Luginbuhl LM, Newman TB, Pantell RH, Finch SA, Wasserman RC (2008) Office-based treatment and outcomes for febrile infants with clinically diagnosed bronchiolitis. Pediatrics 122: 947–954. doi: 10.1542/peds.2007-3206 PMID: 18977972

6. Greenes DS, Harper MB (1999) Low risk of bacteremia in febrile children with recognizable viral syndromes. Pediatr Infect Dis J 18: 258–261. PMID: 10093948

7. Hall CB, Powell KR, Schnabel KC, Gala CL, Pincus PH (1988) Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial viral infection. J Pediatr 113: 266–271. PMID: 3397789

8. Thorburn K, Harigopal S, Reddy V, Taylor N, van Saene HK (2006) High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis. Thorax 61: 611–615. PMID: 16537670

9. Randolph AG, Reder L, Englund JA (2004) Risk of bacterial infection in previously healthy respiratory syncytial virus-infected young children admitted to the intensive care unit. Pediatr Infect Dis J 23: 990–994. PMID: 15545852

10. Jansen AG, Sanders EA, VDE AM, VANL, Hoes AW, et al. (2008) Invasive pneumococcal and meningococcal disease: association with influenza virus and respiratory syncytial virus activity? Epidemiol Infect 136: 1448–1454. doi: 10.1017/S0950268807000271 PMID: 18211724

11. Hishiki H, Ishiwada N, Fukasawa C, Abe K, Hoshino T, et al. (2011) Incidence of bacterial coinfection with respiratory syncytial virus bronchopulmonary infection in pediatric inpatients. J Infect Chemother 17: 87–90. doi: 10.1007/s10156-10010-10097-x Epub 12010 Aug 10111. PMID: 20700753

12. Bloomfield P (2004) Bacteraemia and antibiotic use in respiratory syncytial virus infections. Archives of Disease in Childhood 89: 363–367. PMID: 1503849

13. Weinberger DM, Givon-Lavi N, Shemer-Avni Y, Bar-Ziv J, Alonso WJ, et al. (2013) Influence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel. Emerg Infect Dis 19: 1084–1091. doi: 10.3201/eid1907.121625 PMID: 23763864

14. Sacco RE, McGill JL, Pillatzki AE, Palmer MV, Ackermann MR (2014) Respiratory syncytial virus infection in cattle. Vet Pathol 51: 427–436. doi: 10.1177/0300985813501341 PMID: 24009269

15. Fitzgerald DA, Kilham HA (2004) Bronchiolitis: assessment and evidence-based management. Med J Aust 180: 399–404. PMID: 15087930

16. Farley R, Spurling GK, Eriksson L, Del Mar CB (2014) Antibiotics for bronchiolitis in children under two years of age. Cochrane Database Syst Rev 10: CD005189. doi: 10.1002/14651858.CD005189.pub4 PMID: 25300167

17. Schrenzel J (2007) Clinical relevance of new diagnostic methods for bloodstream infections. Int J Antimicrob Agents 30 Suppl 1: S2–6. PMID: 17884355

18. Thibeault R, Gilca R, Cote S, De Serres G, Boivin G, et al. (2007) Antibiotic use in children is not influenced by the result of rapid antigen detection test for the respiratory syncytial virus. J Clin Virol 39: 169–174. PMID: 17532258

19. Behrendt CE, Decker MD, Burch DJ, Watson PH (1998) International variation in the management of infants hospitalized with respiratory syncytial virus. International RSV Study Group. Eur J Pediatr 157: 215–220. PMID: 9537488

20. Melendez E, Harper MB (2003) Utility of sepsis evaluation in infants 90 days of age or younger with fever and clinical bronchiolitis. Pediatr Infect Dis J 22: 1053–1056. PMID: 14688564
23. Hall C (2009) Respiratory syncytial virus. Feigin and Cherry's Textbook of Pediatric Infectious Diseases. 6th ed. Philadelphia: Saunders Elsevier. pp. 2462–2487.